ASCO News In Brief: Immunomedics CEA-Scan
Immunomedics CEA-Scan: Diagnostic imaging agent shows 92% specificity rate in predicting which breast lesions were not cancerous in patients with inconclusive mammography findings requiring surgical biopsies. Results of the 42-patient study were reported by Dutzu Rosner, MD, State University of New York, Buffalo. In an 84-patient colorectal cancer study, CEA-Scan correctly diagnosed disease in 36 (61%) of the 59 patients who had a previous CT-negative scan. CEA-Scan became "approvable" on April 9 and the company says it is awaiting FDA approval of product labeling...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth